

WuXi AppTec (603259 CH)

Accelerated backlog growth with further guidance raise in 3Q26

WuXi AppTec (WXAT) delivered another strong quarter: 3Q26 revenue rose 38.0% YoY, with continuing-operations revenue up 43.5% YoY, while adj. non-IFRS net profit increased 61.3% YoY. Notably, backlog as of end-3Q26 reached RMB76.74bn, up 36.4% YoY, accelerating from 25.2% YoY as of end-2Q26. Per mgmt., 9M26 new bookings increased over 60% YoY, providing further fundamental support for earnings outlook. Once again, mgmt. raised 2026 revenue guidance to RMB61.0–61.9bn from RMB58.5–60.5bn and continuing-operations growth to 40–42% YoY from 35–39% YoY. Mgmt. maintained its stable adj. non-IFRS net-margin outlook, and narrowed capex guidance to RMB8.0–8.5bn from RMB7.5–8.5bn.

- **Continuously exceptional growth and pipeline expansion within WuXi Chemistry.** WuXi Chemistry remained the principal growth engine for WXAT, with 3Q26 revenue up 48.6% YoY. Small-molecule D&M revenue grew 54.5% YoY, moderating from 72.7% in 1H26 but still benefiting from high-quality molecule inflows, pipeline progression into later stages and proactive capacity deployment. Mgmt. expects Small-molecule D&M revenue to grow over 50% YoY in 2026. TIDES revenue rose 51.6% YoY, accelerating from 44.3% in 1H26 and leading mgmt. to guide up TIDES growth to ~47% in 2026. The segment added eight Phase III or commercial projects in 3Q26, bringing 9M26 additions to 23, the highest in Company's history. The start of the new Changzhou site underscores mgmt's confidence in sustained demand. Overall, WXAT now has 20 plants for small molecules and peptide projects at various stages of design preparation, construction or launch readiness.
- **Broad-based acceleration of early-stage services.** WuXi Testing's 3Q26 revenue grew 32.7% YoY, versus 31.5% in 1H26, underpinned by robust safety-assessment revenue growth of 40.6% in 9M26. WuXi Biology revenue rose 14.4% YoY in 3Q26, improving from 11.2% in 1H26. Small-molecule drug discovery within Chemistry grew 16.8% YoY, sharply above 1H26's 5.6% YoY. Together, these trends indicate improving early-stage R&D demand, with AIDD customers and new modalities providing incremental opportunities for WXAT as global biotech funding continues to recover.
- **Normal volatility of quarterly margins.** Although 3Q26 GPM and NPM declined sequentially from 2Q26, 9M26 GPM/ adj. NPM still expanded 7.6ppt/ 8.3ppt YoY, respectively. Quarterly fluctuations are normal in our view, given the project mix, delivery schedules of key projects, new-capacity ramp-up and FX movements. Mgmt. aims to share part of its efficiency gains with customers and employees rather than maximizing near-term margins. We therefore view the sequential margin moderation in 3Q26 as normal quarterly volatility, with profitability remaining resilient.
- **Maintain BUY.** To factor in the strong momentum of Chemistry segment, we raise our earnings forecasts, expecting revenue to grow by 35.1%/ 18.7%/ 15.7% YoY (for continuing operations: 41.4%/ 18.7%/ 15.7% YoY) and adj. net profit to grow by 68.4%/ 18.8%/ 14.4% YoY in 2026E/ 27E/ 28E, respectively. Hence, we raise our DCF-based TP from RMB170.00 to RMB190.00 (WACC: 9.39%, terminal growth: 2.00%; both unchanged).

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (RMB mn)	39,241	45,456	61,395	72,864	84,334
YoY growth (%)	(2.7)	15.8	35.1	18.7	15.7
Adjusted net profit (RMB mn)	10,583	14,957	25,185	29,907	34,209
YoY growth (%)	(2.5)	41.3	68.4	18.8	14.4
EPS (Adjusted) (RMB)	3.67	5.23	8.64	9.85	11.27
Consensus EPS (RMB)	na	na	7.78	9.16	10.69
P/E (Adjusted) (x)	38.6	27.0	17.0	14.4	12.6

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price RMB190.00
(Previous TP RMB170.00)
Up/Downside 34.3%
Current Price RMB141.48

China Healthcare

Jill WU, CFA
(852) 3900 0842
jillwu@cmbi.com.hk

Benchen HUANG, CFA
huangbenchen@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	429,378.2
Avg 3 mths t/o (RMB mn)	7,520.0
52w High/Low (RMB)	167.96/87.62
Total Issued Shares (mn)	3034.9

Source: FactSet

Shareholding Structure

HK investors	28.5%
Ge Li and concerted parties	16.1%


Source: Company report

Share Performance

	Absolute	Relative
1-mth	-12.9%	-7.1%
3-mth	13.5%	20.0%
6-mth	40.7%	57.6%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	61,395	72,864	84,334	59,709	70,608	81,295	2.82%	3.20%	3.74%
Gross profit	33,718	39,389	44,272	32,667	36,115	40,973	3.22%	9.06%	8.05%
Operating profit	27,772	33,383	38,122	27,289	30,320	34,545	1.77%	10.10%	10.36%
Non-IFRS net profit	25,185	29,907	34,209	23,788	27,335	31,058	5.87%	9.41%	10.14%
Non-IFRS EPS (RMB)	8.64	9.85	11.27	8.16	9.16	10.41	5.87%	7.57%	8.29%
Gross margin	54.92%	54.06%	52.50%	54.71%	51.15%	50.40%	+0.21ppt	+2.91ppt	+2.10ppt
Operating margin	45.24%	45.81%	45.20%	45.70%	42.94%	42.49%	-0.47ppt	+2.87ppt	+2.71ppt
Net margin	41.02%	41.04%	40.56%	39.84%	38.71%	38.20%	+1.18ppt	+2.33ppt	+2.36ppt

Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	61,395	72,864	84,334	60,317	72,916	85,992	1.79%	-0.07%	-1.93%
Gross profit	33,718	39,389	44,272	31,928	38,603	45,675	5.61%	2.04%	-3.07%
Operating profit	27,772	33,383	38,122	27,351	32,413	38,231	1.54%	2.99%	-0.29%
Non-IFRS net profit	25,185	29,907	34,209	22,705	26,830	31,609	10.92%	11.47%	8.22%
Non-IFRS EPS (RMB)	8.64	9.85	11.27	7.78	9.16	10.69	11.01%	7.54%	5.43%
Gross margin	54.92%	54.06%	52.50%	52.93%	52.94%	53.12%	+1.99ppt	+1.12ppt	-0.62ppt
Operating margin	45.24%	45.81%	45.20%	45.35%	44.45%	44.46%	-0.11ppt	+1.36ppt	+0.74ppt
Net margin	41.02%	41.04%	40.56%	37.64%	36.80%	36.76%	+3.38ppt	+4.25ppt	+3.81ppt

Source: Bloomberg, CMBIGM estimates

Figure 3: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	32,209	34,583	39,322	44,451	49,806	55,307	60,862	66,367	71,706	76,758
Tax rate	17.69%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%
EBIT*(1-tax rate)	26,511	29,395	33,424	37,784	42,335	47,011	51,733	56,412	60,950	65,244
+ D&A	3,040	3,707	4,285	4,799	5,327	5,860	6,387	6,898	7,381	7,824
- Change in working capital	-2,011	-2,488	-2,563	-2,870	-3,186	-3,505	-3,820	-4,126	-4,414	-4,679
- Capex	-18,250	-9,000	-8,000	-8,000	-8,000	-8,000	-8,000	-8,000	-8,000	-8,000
FCFF	9,291	21,615	27,146	31,713	36,476	41,366	46,300	51,185	55,917	60,389
Terminal value										834,081
Terminal growth rate										2.00%
WACC										9.39%
Cost of Equity										11.95%
Cost of Debt										4.00%
Equity Beta										0.90
Risk Free Rate										3.00%
Market Risk Premium										10.00%
Target Debt to Asset ratio										30.00%
Effective Corporate Tax Rate										15.00%
PV of terminal value (RMB mn)										340,119
Total PV (RMB mn)										556,262
Net debt (RMB mn)										-20,366
Equity value (RMB mn)										576,629
# of shares (mn)										3,035
Price per share (RMB per share)										190.00

Source: CMBIGM estimates

Figure 4: Sensitivity analysis of DCF model (RMB)

		WACC				
		8.39%	8.89%	9.39%	9.89%	10.39%
Terminal growth rate	3.00%	252.13	228.60	208.82	191.98	177.48
	2.50%	236.92	216.29	198.73	183.61	170.46
	2.00%	224.09	205.77	190.00	176.29	164.27
	1.50%	213.12	196.67	182.38	169.85	158.79
	1.00%	203.64	188.73	175.67	164.13	153.88

Source: CMBIGM estimates

Risks:

1) Uncertainties in the recovery trend of global biotech funding and demand from biotech clients; 2) uncertainties in the demand trend of global mid- and large-size pharmaceutical companies amid the challenging macro and geopolitical environment; 3) slower-than-expected delivery of PhIII and commercial projects, leading to slower revenue growth in the future; 4) failure in obtaining key projects due to various factors, such as the lack of necessary technologies and customers' concerns about geopolitical uncertainties.

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Revenue	40,341	39,241	45,456	61,395	72,864	84,334
Cost of goods sold	(23,729)	(22,965)	(23,801)	(27,677)	(33,475)	(40,062)
Gross profit	16,612	16,277	21,655	33,718	39,389	44,272
Operating expenses	(5,318)	(5,164)	(4,949)	(5,946)	(6,006)	(6,150)
Selling expense	(701)	(745)	(807)	(863)	(878)	(932)
Admin expense	(2,879)	(2,879)	(2,661)	(3,329)	(3,338)	(3,357)
R&D expense	(1,441)	(1,239)	(1,119)	(1,253)	(1,268)	(1,299)
Others	(297)	(301)	(361)	(501)	(522)	(562)
Operating profit	11,294	11,112	16,706	27,772	33,383	38,122
Gain/loss on financial assets at FVTPL	(38)	187	(137)	284	200	200
Investment gain/loss	234	604	8,588	4,228	600	600
Net interest income/(expense)	338	787	(398)	(56)	486	618
Other income/expense	4	(1,150)	(853)	(75)	400	400
Pre-tax profit	11,832	11,540	23,906	32,153	35,069	39,939
Income tax	(2,132)	(1,972)	(4,573)	(5,688)	(5,260)	(5,991)
After tax profit	9,700	9,568	19,333	26,465	29,809	33,949
Minority interest	(94)	(117)	(182)	(79)	(89)	(101)
Net profit	9,607	9,450	19,151	26,386	29,719	33,847
Adjusted net profit	10,854	10,583	14,957	25,185	29,907	34,209
Gross dividends	2,882	2,835	6,755	7,916	8,916	10,154

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Current assets	30,422	38,690	61,677	66,560	81,549	103,130
Cash & equivalents	13,764	18,322	35,131	37,571	48,873	66,530
Account receivables	7,922	8,044	7,281	10,350	12,283	14,217
Inventories	4,736	5,400	8,993	8,368	10,121	12,113
Prepayment	244	226	247	247	247	247
Financial assets at FVTPL	11	1,234	5,806	5,806	5,806	5,806
Other current assets	3,746	5,464	4,218	4,218	4,218	4,218
Non-current assets	43,247	41,636	41,444	60,987	67,090	71,666
PP&E	17,190	18,784	20,000	25,517	31,119	35,143
Deferred income tax	367	473	531	531	531	531
Investment in JVs & assos	2,216	2,326	2,145	2,145	2,145	2,145
Intangibles	1,864	1,575	1,281	1,148	1,016	883
Goodwill	1,821	972	864	864	864	864
Financial assets at FVTPL	8,626	8,943	8,131	22,506	23,306	24,106
Other non-current assets	11,164	8,562	8,492	8,275	8,109	7,992
Total assets	73,669	80,326	103,121	127,548	148,640	174,796
Current liabilities	14,756	16,226	19,235	21,668	23,867	26,229
Short-term borrowings	3,667	1,243	5,986	7,986	8,986	9,986
Account payables	1,645	1,764	2,450	2,882	4,082	5,444
Tax payable	1,374	1,211	2,763	2,763	2,763	2,763
Other current liabilities	8,070	12,008	8,037	8,037	8,037	8,037
Non-current liabilities	3,396	5,014	3,638	10,582	10,582	10,582
Long-term borrowings	687	2,960	1,819	1,819	1,819	1,819
Bond payables	0	0	0	6,944	6,944	6,944
Obligations under finance leases	1,099	547	455	455	455	455
Other non-current liabilities	1,610	1,508	1,364	1,364	1,364	1,364
Total liabilities	18,152	21,240	22,873	32,250	34,450	36,812
Share capital	2,969	2,888	2,984	2,984	2,984	2,984
Capital surplus	28,401	24,338	33,077	51,548	72,351	96,044
Other reserves	23,753	31,407	43,651	40,151	38,151	38,151
Total shareholders equity	55,122	58,633	79,712	94,683	113,486	137,179
Minority interest	395	453	535	615	704	805
Total equity and liabilities	73,669	80,326	103,121	127,548	148,640	174,796

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	11,832	11,540	23,906	32,153	35,069	39,939
Depreciation & amortization	2,288	2,769	3,387	2,903	3,520	4,048
Tax paid	(2,132)	(1,972)	(4,573)	(5,688)	(5,260)	(5,991)
Change in working capital	(105)	(926)	(94)	(2,011)	(2,488)	(2,563)
Others	1,504	996	(5,423)	(4,141)	(1,109)	(1,241)
Net cash from operations	13,387	12,407	17,203	23,217	29,732	34,193
Investing						
Capital expenditure	(5,517)	(4,003)	(5,538)	(8,250)	(9,000)	(8,000)
Acquisition of subsidiaries/ investments	(22)	0	0	0	0	0
Net proceeds from disposal of short-term investments	(2,321)	(2,013)	132	(10,000)	0	0
Others	299	498	3,461	0	0	0
Net cash from investing	(7,561)	(5,518)	(1,945)	(18,250)	(9,000)	(8,000)
Financing						
Dividend paid	(2,756)	(3,085)	(4,992)	(7,972)	(8,430)	(9,537)
Net borrowings	178	3,320	3,563	8,944	1,000	1,000
Proceeds from share issues	247	196	7,046	0	0	0
Others	(1,610)	(4,264)	(4,493)	(3,500)	(2,000)	0
Net cash from financing	(3,941)	(3,832)	1,124	(2,527)	(9,430)	(8,537)
Net change in cash						
Cash at the beginning of the year	7,984	10,001	13,445	35,131	37,571	48,873
Exchange difference	132	388	(370)	0	0	0
Cash at the end of the year	10,001	13,445	29,456	37,571	48,873	66,530
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	2.5%	(2.7%)	15.8%	35.1%	18.7%	15.7%
Gross profit	13.2%	(2.0%)	33.0%	55.7%	16.8%	12.4%
Operating profit	21.4%	(1.6%)	50.3%	66.2%	20.2%	14.2%
Net profit	9.0%	(1.6%)	102.6%	37.8%	12.6%	13.9%
Adj. net profit	15.5%	(2.5%)	41.3%	68.4%	18.8%	14.4%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	41.2%	41.5%	47.6%	54.9%	54.1%	52.5%
Operating margin	28.0%	28.3%	36.8%	45.2%	45.8%	45.2%
Adj. net profit margin	26.9%	27.0%	32.9%	41.0%	41.0%	40.6%
Return on equity (ROE)	18.9%	16.6%	27.7%	30.3%	28.6%	27.0%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Net debt to equity (x)	(0.2)	(0.2)	(0.3)	(0.2)	(0.3)	(0.3)
Current ratio (x)	2.1	2.4	3.2	3.1	3.4	3.9
Receivable turnover days	63.2	74.3	61.5	61.5	61.5	61.5
Inventory turnover days	80.0	80.6	110.4	110.4	110.4	110.4
Payable turnover days	75.6	74.6	75.5	75.5	75.5	75.5
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E (diluted)	38.2	38.6	27.0	17.0	14.4	12.6
P/B	7.5	6.9	5.0	4.3	3.8	3.1
P/CFPS	31.0	32.9	23.5	17.8	14.4	12.6
Div yield (%)	0.7	0.7	1.7	1.9	2.1	2.4

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, has been prepared and distributed in Hong Kong by CMBIGM under its regulatory framework for the regulated activities licensed and regulated by the Securities and Futures Commission of Hong Kong. The report is solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed, directly or indirectly, to any other person, published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request. If there is any inconsistency between the Chinese and English versions of this Important Disclosure, the English version shall prevail.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.